284 related articles for article (PubMed ID: 32755987)
1. Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma.
Harker-Murray PD; Pommert L; Barth MJ
J Natl Compr Canc Netw; 2020 Aug; 18(8):1125-1134. PubMed ID: 32755987
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
3. Primary Mediastinal B-Cell Lymphoma in Children and Young Adults.
Forlenza CJ; Chadburn A; Giulino-Roth L
J Natl Compr Canc Netw; 2023 Mar; 21(3):323-330. PubMed ID: 36898366
[TBL] [Abstract][Full Text] [Related]
4. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
[TBL] [Abstract][Full Text] [Related]
7. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
9. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
10. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
11. Noncellular Immune Therapies for Non-Hodgkin Lymphoma.
Herrera AF
Hematol Oncol Clin North Am; 2019 Aug; 33(4):707-725. PubMed ID: 31229164
[TBL] [Abstract][Full Text] [Related]
12. [Recent advances in pediatric non-Hodgkin lymphoma. Report on a retrospective single-center cohort and review of the literature].
Szegedi I; Gáspár I; Gyurina K; Zele Z; Kiss C
Magy Onkol; 2018 Dec; 62(4):204-213. PubMed ID: 30540862
[TBL] [Abstract][Full Text] [Related]
13. Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.
Gordon MJ; Sureda A; Westin JR
Leuk Lymphoma; 2022 Sep; 63(9):2041-2051. PubMed ID: 35549635
[TBL] [Abstract][Full Text] [Related]
14. Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives.
Worch J; Rohde M; Burkhardt B
Pediatr Hematol Oncol; 2013 Sep; 30(6):465-83. PubMed ID: 23570584
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
16. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Osumi T; Mori T; Fujita N; Saito AM; Nakazawa A; Tsurusawa M; Kobayashi R
Pediatr Blood Cancer; 2016 Oct; 63(10):1794-9. PubMed ID: 27314926
[TBL] [Abstract][Full Text] [Related]
17. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
19. Antibody and immunotherapy in diffuse large B-cell lymphoma.
Barraclough A; Hawkes EA
Semin Hematol; 2023 Nov; 60(5):338-345. PubMed ID: 38072722
[TBL] [Abstract][Full Text] [Related]
20. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study.
Samochatova EV; Maschan AA; Shelikhova LN; Myakova NV; Belogurova MB; Khlebnikova OP; Shamardina AV; Ryskal OV; Roumiantseva JV; Konovalov DM; Dubrovina ME; Rumyantsev AG
J Pediatr Hematol Oncol; 2014 Jul; 36(5):395-401. PubMed ID: 23823112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
